

Inspectorate Program  
Compliance and Enforcement  
2301 Midland Avenue, 2<sup>nd</sup> Floor  
Scarborough, ON M1P 4R7

2014/09/08

Reference #: D2 14 57  
D2 14 58  
D2 14 59

Professor Amir Attaran, DPhil, LLB, MS, BA  
Canada Research Chair in Law, Population Health and Global Development Policy  
Faculties of Law and Medicine; University of Ottawa  
One Stewart Street  
Ottawa, ON K1N 6N5  
[amir@amirattaran.com](mailto:amir@amirattaran.com)

Dear Professor:

Thank you for contacting Health Canada's Inspectorate with your information on the incident dated July 7, 2014 concerning various drugs sold by York Pharmacy, CanDrugs Pharmacy and Canada Drugs.

The information you have provided helps Health Canada deliver our national compliance and enforcement program. Personal information is protected under the provisions of the Privacy Act. The Act provides you with a right of access and to change incorrect information. Should you require clarification about this statement, please refer to our website <http://hc-sc.gc.ca/ahc-asc/activit/atip-aiprp/index-eng.php>.

We invite you to visit the Health Canada website to learn how the Inspectorate meets its mandate [http://www.hc-sc.gc.ca/dhp-mps/compli-conform/index\\_e.html](http://www.hc-sc.gc.ca/dhp-mps/compli-conform/index_e.html).

Health Canada prioritizes its work according to the risk to health that the incident may pose to Canadians. Incidents that present a potentially higher risk to health will be actioned first. Incidents of low or nominal risk will be assessed and entered into our tracking system for possible future compliance action as deemed appropriate. Please note that we may need to contact you to obtain additional information. If you wish to provide additional information regarding this matter, please quote the reference number above when contacting our office.

Health Canada resolves incidents of non-compliance with the *Food and Drugs Act* and its associated *Regulations* that are brought to its attention using various regulatory tools. The tools used are based on the risk associated with the product and may include recommending a recall of the product, publishing an advisory to inform Canadians of the action taken, seizure of the product to remove it from the market, refusal of entry of the product into Canada, and in certain cases, the referral of serious matters to the Public Prosecution Service of Canada for prosecution as per the Compliance and Enforcement Policy.<sup>1</sup>

We thank you again for taking the time to bring your complaint to our attention.

Yours truly,

Angela Leung  
A/Supervisor  
Drug Compliance Verification & Investigation Unit 2  
Tel: 416-973-4094  
E-mail: [angela.leung@hc-sc.gc.ca](mailto:angela.leung@hc-sc.gc.ca)

<sup>1</sup> [http://www.hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/pol/pol\\_1\\_tc-tm-eng.php](http://www.hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/pol/pol_1_tc-tm-eng.php)